No data to show
XASX
BGT
Market cap3mUSD
Jul 14, Last price
0.02AUD
1D
-5.26%
1Q
-41.94%
IPO
-91.82%
Name
Bio-Gene Technology Ltd
Chart & Performance
P/E
—
P/S
261.77
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.55%
Rev. gr., 5y
-48.56%
Revenues
18k
-96.92%
Net income
-2m
L-22.18%
CFO
-3m
L-15.94%
Earnings
Jul 28, 2025
Profile
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 18 -96.92% | 595 -32.36% | |||||||
Cost of revenue | 3,081 | 3,077 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,062) | (2,482) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (604) | (86) | |||||||
Tax Rate | |||||||||
NOPAT | (2,458) | (2,396) | |||||||
Net income | (2,409) -22.18% | (3,096) 10.49% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,979 | ||||||||
BB yield | -21.73% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 23 | 40 | |||||||
Net debt | (2,210) | (2,991) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (2,754) | (3,276) | |||||||
CAPEX | (6) | ||||||||
Cash from investing activities | (6) | ||||||||
Cash from financing activities | 1,979 | (75) | |||||||
FCF | (2,758) | (2,474) | |||||||
| Balance | |||||||||
Cash | 2,210 | 2,991 | |||||||
Long term investments | |||||||||
Excess cash | 2,209 | 2,961 | |||||||
Stockholders' equity | 2,791 | 3,221 | |||||||
Invested Capital | 605 | 301 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 185,818 | 167,768 | |||||||
Price | 0.05 -37.18% | 0.08 -40.00% | |||||||
Market cap | 9,105 -30.42% | 13,086 -34.35% | |||||||
EV | 6,896 | 10,095 | |||||||
EBITDA | (3,024) | (2,436) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||